कंपनी का अवलोकन
Puma Biotechnology, Inc. operates as a biopharmaceutical entity dedicated to the research, development, and commercialization of novel therapies designed to improve cancer treatment outcomes for adult patients with HER2-overexpressing breast cancer, specifically offering NERLYNX as an oral formulation of neratinib. The organization functions within the Healthcare sector and the specialized Biotechnology industry, positioning itself to leverage scientific advancements in oncology for global markets. As of the latest reporting period, the company maintains a market capitalization of $354.61 million and employs a workforce of 179 individuals to execute its strategic initiatives. These valuation and operational metrics indicate that Puma Biotechnology is a mid-cap entity with a focused revenue base of $228.37 million, suggesting a company that relies on high-value, targeted product launches rather than broad-scale pharmaceutical sales to sustain its operations and growth trajectory.
वित्तीय स्वास्थ्य
The company reported a total revenue of $228.37 million for the trailing twelve months, generating a net income of $31.11 million and an EBITDA of $47.44 million, which highlights a significant gap between gross earnings and bottom-line profits due to substantial operating expenses typical in biotechnology. This disparity reveals a cost structure heavily influenced by research, development, and commercialization expenditures that are deducted before arriving at net income, resulting in a profit margin of 13.6%. The firm demonstrates strong cash generation capabilities with free cash flow standing at $30.69 million, providing essential financial flexibility to fund ongoing R&D programs without immediate reliance on external capital markets. Profitability is further underscored by a gross margin of 74.5%, reflecting the high value of intellectual property and low cost of goods sold, while an operating margin of 22.7% indicates efficient management of overhead costs relative to revenue. On the balance sheet, the company holds $97.53 million in cash against $28.55 million in debt, resulting in a debt-to-equity ratio of 21.90%, which suggests a leveraged but manageable capital structure given the cash reserves. Liquidity is robust, evidenced by a current ratio of 2.00, indicating that the company possesses twice the current assets necessary to cover its short-term liabilities. Additionally, the return on equity is 28.0% and the return on assets is 10.9%, metrics that demonstrate effective deployment of shareholder capital and asset utilization to generate returns.
मूल्यांकन आकलन
Valuation multiples for Puma Biotechnology, Inc. include a trailing twelve-month P/E ratio of 11.43 and a forward P/E of 10.72, implying that the market expects earnings growth that would lower the multiple in the coming period. The price-to-book ratio stands at 2.70, indicating that the stock trades at a premium of 170% over its net asset value, a common characteristic for biotechnology firms with valuable intellectual property portfolios. Alternative valuation metrics such as the price-to-sales ratio of 1.55 and an EV/EBITDA of 6.02 provide context for revenue-generating capacity and earnings power relative to enterprise value. Regarding recent price action, the 52-week high is recorded at $7.68 and the low at $2.58; without a specific current share price, the absolute position relative to this range cannot be precisely calculated, but the range itself defines the volatility envelope for the security. The stock exhibits a beta of 1.18, which signifies that its price volatility is 18% higher than the broader market benchmark, reflecting the inherent risks and opportunities associated with the biotechnology sector.
Growth & Income
Revenue growth for the trailing twelve months is 27.7%, while earnings growth is -34.4%, indicating that earnings are growing significantly slower than revenue, likely due to the timing of expense recognition or one-time costs impacting the bottom line. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which means it retains all net income to reinvest into future growth initiatives rather than distributing cash to shareholders. This strategy of zero dividends is sustainable given the current earnings position and allows the firm to allocate resources toward expanding its pipeline of cancer care products. The overall growth and income profile for Puma Biotechnology, Inc. is characterized by strong top-line expansion offset by negative earnings growth, with no income generation via dividends, focusing entirely on capital appreciation potential through product development and commercial success.